Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
NeuroSoV logo — Next-Generation Innovative Therapies to Slowdown Neurologica...

NeuroSoV

Next-Generation Innovative Therapies to Slowdown Neurological Disorders Progression

Founded 2020 Portugal Portugal 4 employees

General Information

Company Name NeuroSoV
Founded Year 2020
Location Portugal Portugal
Employees 4
Social

Get notified when NeuroSoV moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About NeuroSoV

NeuroSoV is a privately held, pre-clinical stage biopharmaceutical company headquartered in Portugal. The company has established a consortium of differentiated international partners and is focused on pioneering the research of disease-modifying treatments for Neurological Disorders. Their goal is to develop innovative molecules that have the potential to change the natural course of disease by leveraging existing pathological mechanisms associated with these disorders. Their multidisciplinary team aims to boost Parkinson's Disease drug development to prevent disease progression. The company's first lead candidate targets one of the main identified underlying Parkinson's Disease pathological mechanisms with a reformulated technology that promises to delay disease progression and enhance patients' quality of life. NeuroSoV is focused on developing new small molecules to tackle the oxidative stress involved in PD, aiming to target NADPH oxidase 1 (NOX1) using an ionic liquid-based NOX1 inhibitor (N1inh-IL). With a founding year of 2020, NeuroSoV is on the cutting edge of innovative therapies for Neurological Disorders. The company's focus on pioneering research and development in this field presents an opportunity for potential investors to join in the quest to make a meaningful impact on public health concerns.

Taxonomy: NeuroSoV, biopharmaceutical company, neurological disorders, Parkinson's Disease, disease-modifying treatments, multidisciplinary team, small molecules, oxidative stress, NADPH oxidase 1, NOX1 inhibitor, innovative therapies, pre-clinical stage, Portugal, drug development

No funding data available for NeuroSoV yet.

Get notified when NeuroSoV raises funding

NeuroSoV Alternatives & Competitors

NeuroSoV vs
Vincere Biosciences
Vincere Biosciences United States

Relentless pursuit of therapeutics that slow/stop the progression of age-related disease

Corporate Round
11 employees
Biotechnology
NeuroSoV vs
Biogenet
Biogenet

Your trusted partner in uncovering the genetic blueprint of health and disease.

Biotechnology
NeuroSoV vs
Cardax, Inc.
Cardax, Inc. United States

Cardax is developing orally bioavailable anti-inflammatory compounds with robust safety for major un...

Post Ipo Equity
17 employees
Biopharma, Biotechnology

FAQ About NeuroSoV

Next-Generation Innovative Therapies to Slowdown Neurological Disorders Progression
NeuroSoV was founded in 2020.
NeuroSoV is headquartered in Portugal.
NeuroSoV has approximately 4 employees.
Top alternatives and competitors to NeuroSoV include Vincere Biosciences, Biogenet, Cardax, Inc., AnnJi Pharmaceutical Co., Ltd., Anavex Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NeuroSoV and Vincere Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors NeuroSoV and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy